Dianthus Therapeutics
Presence
Dianthus Therapeutics is a company listed under the stock ticker DNTH (US).
Acquisition, funding and merger involving Dianthus Therapeutics.
- Dianthus Therapeutics has just announced a $100 Million fundraising (posted on May 5 2022).
Executives
View the org chart displaying its 25 main executives
Most searched biographies at Dianthus Therapeutics
- Marino Garcia, Director, President and Chief Executive Officer
- Lei Meng, Director
- Lonnie Moulder, Chairman of the Board
Popular executive movements at Dianthus Therapeutics
- Jeffrey Stavenhagen has joined the company as Chief Scientific Officer (posted on November 30 2023).
Create your alert
to follow the executive moves at Dianthus Therapeutics.
Biotechnology
Dianthus Therapeutics has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
- Enlaza Therapeutics has just announced a $100 Million fundraising (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Annual Meeting
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- LinkedIn Login, Sign in | LinkedIn
- Home - Dianthus Therapeutics
- Home - Dianthus Therapeutics
- LinkedIn Login, Sign in | LinkedIn
- View more press releases Close
Social media about Dianthus Therapeutics
- Dianthus Therapeutics on Wikipedia, Google News & Yahoo Finance
- Dianthus Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Marino Garcia 
Call Dianthus Therapeutics at +1 781...
